challenges managed to foster a culture of collaboration. At the same time, regulatory issues, the need for standardization, and intellectual property (IP) concerns must be confronted if the current models for drug development are to be refined to encourage robust participation in precompetitive collaborations.
Recognizing the growing importance of precompetitive collaborations in oncology drug development, as well as the challenges these innovative collaborations pose, the National Cancer Policy Forum of the Institute of Medicine (IOM) held a workshop titled Extending the Spectrum of Precompetitive Collaboration in Oncology Research on February 9 and 10, 2010, in Washington, DC. At the workshop, speakers addressed:
Current driving forces for precompetitive collaborations;
Benefits of such collaborations;
Challenges to collaborating;
Types of precompetitive collaborations and what can be shared;
Precompetitive collaboration examples;
Lessons learned and best practices formulated from these examples of collaboration; and
Next steps that could facilitate more precompetitive collaborations in oncology drug development.
This document is a summary of the workshop proceedings. The views expressed in this summary are those of the speakers and discussants, as attributed to them, and are not the consensus views of the workshop participants or members of the National Cancer Policy Forum.
Building on the National Cancer Policy Forum’s workshop, the IOM’s Roundtable on Translating Genomic-Based Research for Health held a related workshop on precompetitive collaboration July 22, 2010, titled Establishing Precompetitive Collaborations to Stimulate Genomics Driven Drug Development. A published summary of that workshop is also planned.
John Wagner, vice president of clinical pharmacology at Merck & Co., began the workshop by pointing out that the notion of precompetitive collaboration is not new, nor is it limited to biomedical applications. A precompetitive collaboration launched by the semiconductor industry